Obermatt
See Similar Stocks →

Sawai Pharmaceutical

TYO:4887 · JP3323040000
PharmaceuticalsLarge

360

44
EV / EBIT58
Price / Owner Earnings33
Owner Earnings Yield73
Dividend Yield85
Price/Sales80
EV / Gross Profit46
Price/Book84
Return on Capital51
Cash Return on Capital57
Return on Equity54
EBIT Margin35
Gross Profitability33
Cash Conversion20
Accruals21
Owner Earnings Margin50
Sales growth26
Profit Growth81
Long-Term EPS Growth92
Owner Earnings Growth45
Reinvestment94
Price momentum72
Debt load31
Refinancing65
Debt Payback29
Liquidity55
Analyst ratings45
Opinion Changes50
Price Target Upside44
Market mood61
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Sawai Pharmaceutical clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryJapan
IndustryPharmaceuticals
SizeLarge
TypePublic Company
ExchangeTSE
Founded1948
Websitesawaigroup.holdings
ISINJP3323040000
Last UpdateApr 2, 2026
Index & Theme
UrologyCardiovascularGastroenterologyHematologyOncologyCentral Nervous SystemRespiratoryBiotechnologyManufacturingPharmaceutical

Description

Sawai Group Holdings Co., Ltd. engages in the manufacture and sale of generic pharmaceutical products. Business Segments The company operates through two primary business segments: the Japan Business segment and the U.S. Business segment. Japan Bu…

Analysis

Middle-of-the-road

Sawai Group Holdings Co., Ltd. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is attractive. The owner-earnings multiple stands at 14.2×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 2% a year, against analyst forecasts of 27%. The price, in other words, assumes less than the experts do.

Growth is moderate; the safety picture is adequate. The company scores 8/20 on our value-creation score: creating some value.

Flags to be aware of: Some accounting patterns deserve a closer look. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
93
2023202420252026

All-time high

98

Jan 2025

All-time low

44

Mar 2026

Average rank

84

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
80
76
91
97
Price/Earnings
34
81
74
97
Price/Book
84
78
71
93
Dividend Yield
85
65
82
92
Value (overall)
88
86
92
100

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Sawai Pharmaceutical with its peers
HUTCHMED (China)
HKG:13
27
CountryHong Kong SAR China
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Pyridam Farma
JKT:PYFA
3
CountrySingapore
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Tsumura
TYO:4540
47
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Daiichi Sankyo
TYO:4568
56
CountryJapan
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Kyongbo Pharmaceutical
KSC:214390
11
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Ono Pharmaceutical
TYO:4528
87
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →